Quince <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Announces $11.5 Million Private Placement, CEO Dirk Thye Purchases $200K in Shares
On June 12, 2025, Quince Therapeutics, Inc. entered into a Securities Purchase Agreement with institutional investors and certain members of the Company's management. The Company will issue and sell a total of 6,671,928 shares of its common stock and pre-funded warrants to purchase up to 2,000,000 shares of common stock. Additionally, accompanying warrants to purchase up to 8,671,928 shares of common stock will be issued. The total gross proceeds from this private placement are approximately $11.5 million. Each share and accompanying warrant are sold at a combined price of $1.325.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-140873), on June 13, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。